Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When Standard BioTools Inc.’s mass cytometry systems shape immunotherapy studies worldwide, even a single line in the 10-K can move markets. Investors often ask, “Where can I review Standard BioTools quarterly earnings report 10-Q filing?” or “How do I track Standard BioTools insider trading Form 4 transactions?” Those answers live inside dense SEC documents—finding them can drain hours.
Stock Titan turns that complexity into clarity. Our AI delivers Standard BioTools SEC filings explained simply, spotlighting revenue from proteomics instruments, R&D cash burn, and obligations tied to leased manufacturing sites. You’ll see each Standard BioTools annual report 10-K simplified and Standard BioTools 8-K material events explained within minutes of hitting EDGAR. Real-time alerts surface Standard BioTools Form 4 insider transactions real-time, ensuring you never miss meaningful Standard BioTools executive stock transactions Form 4. Need faster context? Every Standard BioTools earnings report filing analysis pairs key metrics with peer benchmarks for immediate comparison.
Whether you’re building a valuation model or evaluating management incentives, critical disclosures are one click away:
- Track Standard BioTools proxy statement executive compensation to understand leadership alignment
- Compare margins and backlog across each Standard BioTools quarterly earnings report 10-Q filing
- Receive alerts on emerging risks via Standard BioTools 8-K material events explained
Understanding Standard BioTools SEC documents with AI means spending less time scrolling and more time deciding. Every filing, every footnote—decoded and delivered in real time.
Standard BioTools (LAB) disclosed classification and accounting for the previously announced sale of its SomaScan Business as a discontinued operation. The agreed sale proceeds total $350.0 million plus estimated contingent consideration with an estimated fair value of $396.9 million; the fair value of consideration transferred in the Merger was reported as $444.2 million, and the company recognized a $25.2 million bargain purchase gain. The company allocated $111.9 million of goodwill (100% of total goodwill) to the discontinued operations based on relative fair value, and $30.0 million of deferred revenue related to a Collaboration Agreement was excluded from the disposal group. Management performed recoverability testing on remaining long-lived assets and did not recognize impairment for the periods presented. The filing also discloses continued investments in R&D and commercial infrastructure, a share repurchase authorization up to 50.0 million common shares through March 1, 2026, and maintenance of a valuation allowance against U.S. deferred tax assets.
Standard BioTools Inc. (LAB) furnished a Current Report on Form 8-K stating it issued a press release dated August 11, 2025 that includes information about certain financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1.
The filing specifies that the press release content, excluding the sections titled "Full Year 2025 Revenue Outlook" and "About Standard BioTools Inc." together with the forward-looking statement disclaimer, is incorporated by reference into Item 2.02, while those excluded sections and the disclaimer are incorporated by reference into Item 7.01. The report is furnished, not filed, and is signed by Alex Kim, Chief Financial Officer.
Standard BioTools Inc. (LAB) – Form 4/A (filed 07/30/25)
Director Troy Cox filed an amended Form 4 to correct the share count shown in Column 5 of Table I of the original filing dated 06/24/25. After the correction, Cox is shown as beneficially owning 319,322 shares of LAB common stock. No new acquisitions, dispositions, option exercises, or derivative positions are reported; the filing strictly updates the post-transaction ownership figure. All other data from the original Form 4 remain unchanged. Because the amendment merely revises record-keeping and does not reflect a new transaction, the disclosure is administrative in nature and has negligible economic impact on shareholder value or float.
Standard BioTools (NASDAQ:LAB) submitted a routine Form 4 disclosing director Troy Cox received 94,592 restricted stock units (RSUs) that vest in full by June 20 2026 and a stock option for 125,660 shares at an exercise price of $1.05, vesting in 12 equal monthly installments beginning July 20 2025.
Following these grants, Cox’s beneficial ownership stands at 256,412 common shares. No shares were sold, and the filing contains no additional transactions or financial disclosures.
Standard BioTools Inc. (LAB) has reported insider equity awards to Director Fenel M. Eloi on Form 4 dated 06/24/2025. On 06/20/2025 Eloi received 94,592 Restricted Stock Units (RSUs) valued at $0 per unit and 125,660 non-qualified stock options with an exercise price of $1.05 per share. The RSUs vest in full on the earlier of 20 June 2026 or one day before the next annual meeting, while the options vest in twelve equal monthly tranches beginning 20 July 2025 and expire 20 June 2035.
After these grants, Eloi’s direct holdings increase to 236,183 common shares and 125,660 options. The transaction code “A” indicates the shares and options were awarded by the company rather than purchased on the open market. No Rule 10b5-1 trading plan was noted, and the filing concerns routine director compensation rather than open-market buying or selling.
Standard BioTools Inc. (LAB) – Form 4 insider transaction filed 06/24/2025
Director Thomas D. Carey reported two equity awards dated 06/20/2025:
- 94,592 Restricted Stock Units (RSUs) that vest in full on the earlier of 20 Jun 2026 or one day prior to the company’s next annual meeting, contingent on continued service. Each RSU converts into one share of common stock upon vesting.
- 188,490 stock options with a $1.05 exercise price, becoming exercisable in 12 equal monthly installments beginning 20 Jul 2025 and expiring 20 Jun 2035, also subject to continued service.
Following these grants, Carey’s direct beneficial ownership stands at 194,058 common shares. No dispositions were reported; the grants were acquired at $0 cost (for RSUs) and standard option pricing applies upon exercise. The filing does not reference any 10b5-1 trading plan.
The reported awards reflect routine director compensation and do not involve open-market purchases or sales; therefore, immediate dilution or cash impact to shareholders is negligible. Investors may view the transaction primarily as a governance disclosure rather than a signal of near-term fundamentals.
Standard BioTools Inc. (LAB) Form 4 filing dated 06/24/2025 details new equity awards granted to director and ≥10% shareholder Eli Casdin.
- Restricted Stock Units (RSUs): 94,592 RSUs awarded on 06/20/2025; they vest in full on the earlier of 06/20/2026 or one day prior to the next annual meeting, conditional on continued service. Each RSU converts into one common share.
- Stock Options: Option covering 125,660 shares with a $1.05 exercise price, granted 06/20/2025. The option vests in 12 equal monthly installments beginning 07/20/2025 and expires 06/20/2035.
- Post-transaction ownership: 2,901,062 shares held directly. Through affiliated investment funds, Casdin controls an additional 76,075,636 shares (13,939,637 via Casdin Private Growth Equity Fund II, 2,744,219 via Casdin Private Growth Equity Fund, and 59,391,780 via Casdin Partners Master Fund).
- Role: Casdin is both a director and ≥10% beneficial owner, indicating significant ongoing influence.
No purchase or sale of shares occurred; the awards were granted at no cost, reflecting routine director compensation and aligning incentives with shareholders. The filing does not disclose any earnings data, cash consideration, or changes to company guidance.
FAQ
What is the current stock price of STANDARD BIOTOOLS (LAB)?
What is the market cap of STANDARD BIOTOOLS (LAB)?
